NORGESIC FORTE
LOE ApproachingNDAORALTABLET
Approved
Mar 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NORGESIC FORTE by Bausch + Lomb is clinical pharmacology orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formulation. First approved in 1964.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORGESIC FORTE is an oral combination tablet containing orphenadrine citrate, aspirin, and caffeine approved in 1964. It is indicated for the treatment of acute musculoskeletal pain and muscle spasm through a centrally acting mechanism that blocks facilitatory functions of the reticular formation in the brain stem. The drug does not produce myoneural block and works synergistically with aspirin's analgesic and anti-inflammatory properties.
$0.004BPart D
LOE ApproachingMature product in advanced decline with minimal market presence (1,100 Part D claims in 2023), indicating a small, legacy team focused on maintenance rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Orphenadrine citrate is a centrally acting (brain stem) compound which in animals selectively blocks facilitatory functions of the reticular formulation. Orphenadrine does not produce myoneural block, nor does it affect crossed extensor reflexes. Orphenadrine prevents…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORGESIC FORTE offers limited career growth potential given its LOE-approaching status, minimal Part D spending ($4M), and only 1 linked job listing. Professionals on this team are typically managing decline, ensuring compliance, and supporting legacy customers rather than driving innovation or market expansion.
Worked on NORGESIC FORTE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.